

Continuous vital signs monitoring in healthy volunteers undergoing a COVID-19 challenge trial

Submission date 13/09/2022	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/09/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 02/08/2024	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Currently, for nurses to watch vital signs closely, namely heart rate, respiratory rate, blood pressure, temperature and oxygen saturation, participants are either attached to a static machine by the participant's bedside using wires, or staff visit the participant every few hours to measure these vital signs using a portable wired machine. It is now possible to closely monitor participants using small devices which attach to the wrist, finger or chest. These devices allow nursing staff to continually watch vital signs data from these participants when they are away from their bedside. These machines are also wireless and portable, so they do not stop participants from moving around, which is important for recovery, and are comfortable to wear. In past years, researchers have tested these devices and developed a system to allow the clinical staff to see the continuous vital signs. Although a lot more is now known about the physiological impact of COVID-19, there is still a lack of research on the trajectory of vital signs for participants with this new condition. This system offers an opportunity to examine the patterns of vital signs both before and after inoculation with the virus. The aim of this study is to collect preliminary continuous vital sign data to investigate the feasibility of using these wearables to monitor and detect vital sign variation. In this initial study the researchers will only be collecting and analysing data from the COV-CHIM01 trial participants and the system will not be actively used for real-time monitoring.

Who can participate?

Participants must be aged 18 years or over and participating in the COV-CHIM01 trial

What does the study involve?

Those who agree to take part will be asked to wear two devices from Day -1 to Day 12 of their stay. Between them, these devices will record heart rate, respiratory rate and blood pressure. Although participants will be encouraged to wear these as often as possible, they can remove one or more devices temporarily, or choose to remove the system completely at any time. Participants will be asked to log the times when devices are removed and complete a questionnaire about how comfortable the devices were. As part of the COV-CHIM01 challenge study, the study team will measure participants' vital signs four times daily (heart rate, blood

pressure, oxygen saturation levels, breathing rate, and temperature) and will have daily COVID-19 swabs. These measurements will be compared with measurements taken by the two wearable devices. They will also be used to interpret the results depending on whether or not participants develop a COVID-19 infection.

What are the possible benefits and risks of participating?

There is no direct benefit from taking part in this study, however, participation will contribute to current evidence that will support further research on wearable ambulatory monitoring systems and a better understanding of vital sign trajectories before and after infection.

Where is the study run from?

University of Oxford (UK)

When is the study starting and how long is it expected to run for?

February 2022 to January 2028

Who is funding the study?

The NIHR Oxford Biomedical Research Centre (UK)

Who is the main contact?

Prof. Peter Watkinson, rachel.henning@ndcn.ox.ac.uk

Contact information

Type(s)

Principal Investigator

Contact name

Prof Peter Watkinson

ORCID ID

<http://orcid.org/0000-0003-1023-3927>

Contact details

Critical Care Research Group

Kadoorie Centre

Level 3

John Radcliffe Hospital

Oxford

United Kingdom

OX3 9DU

+44 (0)1865 231448

rachel.henning@ndcn.ox.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

v3.0

Study information

Scientific Title

The virtual High Dependency Unit (vHDU) Challenge study: continuous vital signs monitoring in COVID-19 challenge participants

Acronym

vHDU-CS

Study objectives

To determine the feasibility of using wearable monitors to examine patterns of vital signs, before and after inoculation with the SARS-CoV-2 virus, within a medical research facility.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/09/2022, Medical Sciences Interdivisional Research Ethics Committee (Research Services, Boundary Brook House, Churchill Drive, Headington, Oxford, OX3 7GB, UK; +44 (0)1865 616575; ethics@medsci.ox.ac.uk), ref: R80395/RE001

Study design

Single-centre observational study

Primary study design

Observational

Secondary study design

Case series

Study setting(s)

Other

Study type(s)

Screening

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

The study will be conducted in the Clinical Research Facility at the Churchill Hospital in Oxford. The COV-CHIM01 trial participants (also the study population) are admitted 2 days prior to exposure to the SARS-CoV-2 virus. The virus exposure will be entirely managed by the COV-CHIM01 trial team.

Informed consent will be taken from willing participants after they are admitted to the Clinical Research Facility, but before the exposure to the virus. Following this, recruited participants will then have the VitalPatch (adhesive chest patch collecting heart rate and respiratory rate) and Aktiia (wrist-worn unit collecting blood pressure) devices attached and will be instructed in their use by a member of the research team. Baseline blood pressure and temperature will be recorded by the research team in order to calibrate the wearable devices.

Recruited participants will be encouraged to wear the two devices (as tolerated) as much as possible including during sleep, from Day -1 of the COV-CHIM01 study (the day before inoculation) to Day 12.

The VitalPatch can be worn continuously, but participants will need to remove the Aktiia for showering, during which time the device can be placed on charge. This will be clearly discussed during the initial consent and specified in the Participant Information Sheet.

They will be visited on Day 6 of their quarantine period by a member of the research team, who will supervise the replacement of the VitalPatch and check the Aktiia device. During this visit participants will be asked to complete a wearability questionnaire.

On Day 12 of their quarantine period they will be visited again and the devices will be removed.

Participants who would prefer to wear only one of either the VitalPatch or the Aktiia will still be included in the study.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

VitalPatch, Aktiia

Primary outcome measure

The feasibility of early detection of COVID-19 infection using data collected by wearable devices and the measured variation in vital signs from continuous monitoring during the course of the study (up to Day 12)

Secondary outcome measures

1. Demographic data collected using a questionnaire at the start of the study
2. Wearability measured using a questionnaire on Day 6 of the study
3. Heart rate, respiratory rate, blood pressure, oxygen saturation, temperature data and infection data collected by the COV-CHIM01 study team at regular intervals based on Challenge

protocol

4. Accelerometer data, heart rate and respiratory rate variability data from the wearable device (VitalPatch) monitored continuously during the course of the study (up to Day 12)

Overall study start date

01/02/2022

Completion date

01/01/2028

Eligibility

Key inclusion criteria

Current inclusion criteria as of 02/08/2024:

1. Participation in the COV-CHIM01/COV-HIC001/COV-CHIM02 study
2. Participant is willing and able to give informed consent for participation in this study
3. Aged 18 years or over

Previous inclusion criteria:

1. Participation in the COV-CHIM01 study
2. Participant is willing and able to give informed consent for participation in this study
3. Aged 18 years or over

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Upper age limit

40 Years

Sex

Both

Target number of participants

45

Key exclusion criteria

1. Intra-cardiac device
2. Known history of cardiac arrhythmias
3. Allergy to adhesives

Date of first enrolment

20/09/2022

Date of final enrolment

01/09/2027

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

The Oxford Clinical Research Facility

Churchill Hospital

Oxford

United Kingdom

OX3 7LE

Sponsor information

Organisation

University of Oxford

Sponsor details

Clinical Trials and Research Governance

Joint Research Office

Block 60

Churchill Hospital

Old Road

Headington

Oxford

England

United Kingdom

OX3 7LE

+44 (0)1865 572221

karl.shepherd@admin.ox.ac.uk

Sponsor type

University/education

Website

<http://www.ox.ac.uk/>

ROR

<https://ror.org/052gg0110>

Funder(s)

Funder type

Research organisation

Funder Name

NIHR Oxford Biomedical Research Centre

Alternative Name(s)

NIHR Biomedical Research Centre, Oxford, OxBRC

Funding Body Type

Private sector organisation

Funding Body Subtype

Research institutes and centers

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The Investigators will be involved in reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study. The authors will acknowledge that the study was funded by NIHR Oxford Biomedical Research Centre. Authorship will be determined in accordance with the ICMJE guidelines and other contributors will be acknowledged.

Members of the COV-CHIM01 research team will also be involved in the manuscript and output writing and will be authored/acknowledged according to ICMJE guidelines.

Intention to publish date

01/01/2024

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available as the data from the wearable devices is linked to another study. In the ethics application this was extensively discussed and it was decided that the dataset will be held in a secure setting behind two doors and restricted access within Kadoorie Centre for Critical Care Research and Education and Institute of Biomedical Engineering secure server.

IPD sharing plan summary

Not expected to be made available